GlassScriptPhysician profile
Jannel Lee-Allen
NPI 1700240819
$46,098.72
in general payments reported to CMS, 2019-2025
31 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.23 · 2020: $89.77 · 2021: $379 · 2022: $964 · 2023: $1,433 · 2024: $2,117 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $6,447 · Travel and Lodging: $2,221 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,830.66 |
| Food and Beverage | $6,447.04 |
| Travel and Lodging | $2,221.40 |
| Education | $100.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $27,872.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $11,086.53 | 2022-2025 | Dupixent |
| Abbvie INC. | $1,359.45 | 2020-2025 | |
| Janssen Biotech, INC. | $999.79 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $885.75 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $583.45 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $565.22 | 2019-2025 | |
| Pfizer INC. | $382.73 | 2023-2025 | |
| Lilly USA, LLC | $277.85 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $211.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $202.94 | 2021-2025 | Sucraid |
| Janssen Scientific Affairs, LLC | $193.86 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $150.47 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $143.70 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $142.90 | 2019-2025 | Ocaliva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $138.54 | 2024 | Dupixent |
| Eisai INC. | $124.78 | 2022 | |
| Celgene Corporation | $116.09 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $114.98 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $103.25 | 2024-2025 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $95.31 | 2022-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $81.63 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $61.61 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $48.89 | 2022-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $38.17 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $35.13 | 2021-2023 | |
| Novo Nordisk INC | $22.56 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $17.68 | 2019 | |
| Daiichi Sankyo INC. | $16.39 | 2022 | |
| Dynavax Technologies Corporation | $14.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jannel Lee-Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.